Davies Kurtis D, Farooqi Midhat S, Gruidl Mike, Hill Charles E, Woolworth-Hirschhorn Julie, Jones Heather, Jones Kenneth L, Magliocco Anthony, Mitui Midori, O'Neill Philip H, O'Rourke Rebecca, Patel Nirali M, Qin Dahui, Ramos Erica, Rossi Michael R, Schneider Thomas M, Smith Geoffrey H, Zhang Linsheng, Park Jason Y, Aisner Dara L
Department of Pathology, University of Colorado-Anschutz Medical Campus, Denver, Colorado.
Department of Pathology, Children's Health & UT Southwestern Medical Center, Dallas, Texas.
J Mol Diagn. 2016 Jul;18(4):572-9. doi: 10.1016/j.jmoldx.2016.03.002. Epub 2016 May 4.
Next-generation sequencing is becoming increasingly common in clinical laboratories worldwide and is revolutionizing clinical molecular testing. However, the large amounts of raw data produced by next-generation sequencing assays and the need for complex bioinformatics analyses present unique challenges. Proficiency testing in clinical laboratories has traditionally been designed to evaluate assays in their entirety; however, it can be alternatively applied to separate assay components. We developed and implemented a multi-institutional proficiency testing approach to directly assess custom bioinformatics and variant interpretation processes. Six clinical laboratories, all of which use the same commercial library preparation kit for next-generation sequencing analysis of tumor specimens, each submitted raw data (FASTQ files) from four samples. These 24 file sets were then deidentified and redistributed to five of the institutions for analysis and interpretation according to their clinically validated approach. Among the laboratories, there was a high rate of concordance in the calling of single-nucleotide variants, in particular those we considered clinically significant (100% concordance). However, there was significant discordance in the calling of clinically significant insertions/deletions, with only two of seven being called by all participating laboratories. Missed calls were addressed by each laboratory to improve their bioinformatics processes. Thus, through our alternative proficiency testing approach, we identified the bioinformatic detection of insertions/deletions as an area of particular concern for clinical laboratories performing next-generation sequencing testing.
新一代测序在全球临床实验室中越来越普遍,正在彻底改变临床分子检测。然而,新一代测序检测产生的大量原始数据以及对复杂生物信息学分析的需求带来了独特的挑战。临床实验室的能力验证传统上旨在评估整个检测;然而,它也可用于单独评估检测组件。我们开发并实施了一种多机构能力验证方法,以直接评估定制生物信息学和变异解读过程。六个临床实验室,均使用相同的商业文库制备试剂盒对肿瘤标本进行新一代测序分析,每个实验室提交了来自四个样本的原始数据(FASTQ文件)。然后对这24个文件集进行去识别处理,并重新分发给其中五个机构,以便根据其经过临床验证的方法进行分析和解读。在这些实验室中,单核苷酸变异的检出率具有较高的一致性,尤其是那些我们认为具有临床意义的变异(一致性为100%)。然而,在具有临床意义的插入/缺失的检出方面存在显著差异,所有参与实验室仅检出了七个中的两个。每个实验室都对漏检情况进行了处理,以改进其生物信息学流程。因此,通过我们的替代能力验证方法,我们确定插入/缺失的生物信息学检测是进行新一代测序检测的临床实验室特别关注的领域。